MCG clinical study was presented at ESC Acute Cardiovascular Care 2018 in March 3rd, in Milan, Italy. This study was conducted in Myanmar, where the locations of the cath-lab are very limited.  MCG was compared with CAG, and it showed high sensitivity and specificity for the presence of severe CAD by CAG (≥ 75%). By Author, it is evaluated as “MCG could be used for prompt detection of severe CAD in order to start appropriate (PCI/Optimal Medical Therapy) treatments in the emerging country such as Myanmar where less medical facilities and skills are available.”

Premier Heart International(PHI) attended the ASEAN CEO Business Matching Meeting for Medical Device held  in Tokyo on 15-16 of March,2018. PHI met a lot of good distributors from Indonesia, Malaysia, Thailand, Vietnam and Taiwan, and talked about sales, marketing and other business opportunities each other. This was really fruitful networking for everyone. PHI will take advantage of these valuable opportunities for expanding MCG business into Asia.